The Immunology and Cancer Program (Program 3) has been an integral component of the UCCRC for more than 20 years. It has 19 members from 5 departments, and is supported by a total of $7,660,269 in peer-reviewed funding (annual direct costs), with $2,154,936 from the NCI. Over the past grant period, program members have produced a total of 387 peer-reviewed publications, including 11% that were intraprogrammatic and 15% that were interprogrammatic collaborations. It is well established that tumors can express antigens that can be recognized by specific T cells or antibodies. Established immunologic therapies in the clinic include allogeneic bone marrow or blood stem cell transplantation, the monoclonal antibodies Herceptin and Rituxan, and the cytokines IL-2 and IFN-cc. However, as fundamental knowledge of the immune system continues to increase at a rapid pace, the potential for improving upon existing immune-based therapies, as well as for developing new immunotherapeutic approaches, continues to expand. The overall goals of the Immunology and Cancer Program are to foster the best possible research that has relevance for the cancer setting, to support an environment that brings new immunology concepts into preclinical models of anti-tumor immunity, and to translate fundamental discoveries into clinical application. A major accomplishment of the Program is the expansion of the clinical/translational component. These goals are supported by severa key Core Facilities, in particular the Flow Cytometry, Fitch Monoclonal Antibody, Immunohistochemistry, and the Human Immunologic Monitoring Cores. The Immunology and Cancer Program also depends on the services of the cGMP Facility (a UCCRC developing core) for preparation of clinical-grade immunotherapeutic products for clinical administration. By incorporating detailed scientific endpoint monitoring into clinical studies, new key information is being generated that has led to the development of new hypotheses that can then be interrogated back in the basic laboratory. Thus, the Immunology and Cancer Program has evolved into a clear example of bi-directional translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014599-37S1
Application #
8518668
Study Section
Special Emphasis Panel (ZCA1-RTRB-N)
Project Start
2012-04-01
Project End
2013-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
37
Fiscal Year
2012
Total Cost
$139,999
Indirect Cost
$51,392
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Lee, Ji-Hye; Park, Beom Seok; Han, Kang R et al. (2018) Insight Into the Interaction Between RNA Polymerase and VPg for Murine Norovirus Replication. Front Microbiol 9:1466
Cheng, Jason X; Chen, Li; Li, Yuan et al. (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9:1163
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70

Showing the most recent 10 out of 668 publications